Orthocell Posts Seventh Straight Record Revenue Quarter
| Stock | Orthocell Ltd (OCC.ASX) |
|---|---|
| Release Time | 6 Jan 2026, 9:33 a.m. |
| Price Sensitive | Yes |
Orthocell Posts Seventh Straight Record Revenue Quarter
- Record quarterly revenue of $3.2 million, up 7% from previous quarter and 45.2% year-over-year
- Seventh consecutive quarter of record revenue, with 10.4% compound quarterly growth rate since Q3 FY24
- Strong performance in existing markets, including initial contributions from the United States
Orthocell Limited (ASX:OCC), a regenerative medicine company, has announced a record quarterly revenue of $3.2 million for the quarter ended 31 December 2025. This result represents a 7.0% increase over the previous quarterly record of $3.0 million achieved in the September 2025 quarter and a 45.2% increase on the prior corresponding period. The record revenue performance was primarily driven by increased market penetration in existing markets, particularly Australia, as well as initial financial contributions from early Remplir surgical cases in the United States. The anticipated growth in Remplir adoption by U.S. surgeons represents the potential for a strong increase in revenue going forward, with momentum expected to build through 2026. Growth in Remplir sales is also expected to be further supported by entry into the Canadian market, with initial sales targeted for the March quarter FY26 and market adoption anticipated to grow steadily throughout 2026. Orthocell maintains robust cash reserves of $49.4 million and is well positioned to support continued commercial expansion, with an R&D tax incentive refund of approximately $3.0 million expected to be received in the March quarter FY26.
Orthocell expects to see a step change in revenue in FY26 as the Remplir rollout in the US$1.6 billion US market continues to gain momentum and the company enters the Canadian market.
Orthocell's hybrid market entry strategy, combining specialist distributors with internal field leadership, is successfully delivering positive momentum in the US market. The company expects this approach to drive rapid product adoption and sustained growth, replicating the successful market entry approach previously implemented in Australia and Singapore.